FABP3 and metabolic disease: Instead, circulating hFABP may well be a marker of cardiomyocyte-specific metabolic disorders as they occur not only during but also before the onset of HF, thus making hFABP a promising candidate biomarker for very early stages of subclinical HF, and for HF prognostication.